HUGGGE Profits For Moderna With COVID VAXX!

Whitney Webb writes:

“COVID-19 erased the regulatory and trial-related hurdles that [biotech/vaccine] manufacturer Moderna could never surmount before… Key issues for the company, including seemingly insurmountable regulatory hurdles and its inability to advance beyond animal trials with its most promising—and profitable—products, were conveniently wiped away, and not a moment too soon. Since January 2020, the value of Moderna’s stock—which had embarked on a steady decline since its IPO—grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine…”

You may also like...

Translate »